Loading…

High macrophage PD-L1 expression not responsible for T cell suppression

•Peritoneal cavity (PerC) cell culture models macrophage (Mϕ)-rich tumor microenvironments.•(TMEs)•PerC T cell proliferation is suppressed by Mϕs.•IFNγ-driven PD-L1 expression increased markedly on PerC Mϕs.•Blocking PD-1/PD-L1 interaction does not relieve suppression. Tumors are often comprised of...

Full description

Saved in:
Bibliographic Details
Published in:Cellular immunology 2018-02, Vol.324, p.50-58
Main Authors: Goldman, Naomi, Lomakova, Yelizavet D., Londregan, Jennifer, Bucknum, Amanda, DePierri, Kelley, Somerville, John, Riggs, James E.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Peritoneal cavity (PerC) cell culture models macrophage (Mϕ)-rich tumor microenvironments.•(TMEs)•PerC T cell proliferation is suppressed by Mϕs.•IFNγ-driven PD-L1 expression increased markedly on PerC Mϕs.•Blocking PD-1/PD-L1 interaction does not relieve suppression. Tumors are often comprised of microenvironments (TMEs) with a high proportion of cells and molecules that regulate immunity. Peritoneal cavity (PerC) cell culture reproduces key features of TMEs as lymphocyte proliferation is suppressed by PerC macrophages (Mϕs). We monitored the expression of T cell stimulatory (Class II MHC, B7) and inhibitory (PD-L1) molecules by PerC APCs before and after culture and report here that IFNγ-driven PD-L1 expression increased markedly on PerC Mϕs after TCR ligation, even more so than seen with direct APC activation by LPS. Considering the high APC composition of and pronounced PD-L1 expression by PerC cells, it was surprising that blocking PD-1/PD-L1 interaction by mAb neutralization or genetic ablation did not relieve suppression. This result parallels TME challenges observed in the clinic and validates the need for further study of this culture model to inform strategies to promote anti-tumor immunity.
ISSN:0008-8749
1090-2163
DOI:10.1016/j.cellimm.2017.12.013